Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 11/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330881 | 0.87 | MTNR1A (0.77) | MTNR1AMTNR1BEPHX2GAAMAPT | |
| SCHEMBL8564600 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BEPHX2GAAMAPT | |
| SCHEMBL19318516 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BEPHX2GAAMAPT | |
| SCHEMBL8564607 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BEPHX2GAAMAPT | |
| SCHEMBL8564595 | 0.86 | MTNR1A (0.76) | MTNR1AMTNR1BEPHX2GAAMAPT | |
| SCHEMBL27057753 | 0.83 | MTNR1A (0.70) | MTNR1AMTNR1BEPHX2 | |
| SCHEMBL7281450 | 0.81 | MTNR1A (0.68) | MTNR1AMTNR1BDRD3 | |
| SCHEMBL16181821 | 0.80 | MTNR1A (0.67) | MTNR1AMTNR1BEPHX2 | |
| SCHEMBL19319093 | 0.80 | MTNR1A (0.66) | MTNR1AMTNR1BEPHX2GAAMAPT | |
| SCHEMBL10974953 | 0.78 | MTNR1A (0.64) | MTNR1AMTNR1BEPHX2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | MTNR1A 3652/4885MTNR1B 3626/4885EPHX2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.